Amicus Therapeutics (FOLD) Worth Watching: Stock Rises 10.3%
Amicus Therapeutics, Inc. (FOLD) was a big mover last session with its shares rising over 10% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company as the stock has gained nearly 53% in the past one-month time frame.
This biopharmaceutical company has seen 2 positive estimate revisions in the last 30 days. The Zacks Consensus Estimate has also moved higher over the same period. This implies solid trading potential for the company. So make sure to keep an eye on this stock going forward to see if yesterday’s rally can turn into more strength down the road.
Amicus Therapeutics currently has a Zacks Rank #2 (Buy) while its Earnings ESP is 0.00%.
Investors interested in the biomedical/gene industry may also consider stocks like Amgen Inc. (AMGN), Illumina Inc. (ILMN) and Gilead Sciences Inc. (GILD). All the three stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
AMICUS THERAPEUTICS INC (FOLD): Free Stock Analysis Report
AMGEN INC (AMGN): Free Stock Analysis Report
ILLUMINA INC (ILMN): Free Stock Analysis Report
GILEAD SCIENCES INC (GILD): Free Stock Analysis Report
Zacks Investment Research